Review Article| Volume 50, ISSUE 1, P101-107, March 2023

Obstetric Indications for Progestin Therapy

  • Rupsa C. Boelig
    Corresponding author.
    Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, 833 Chestnut Street, Level 1, Philadelphia, PA 19107, USA

    Department of Clinical Pharmacology and Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA
    Search for articles by this author


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Obstetrics and Gynecology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Csapo A.I.
        • Pinto-Dantas C.A.
        The effect of progesterone on the human uterus.
        Proc Natl Acad Sci U S A. 1965; 54: 1069-1076
        • Caritis S.N.
        • Feghali M.N.
        • Grobman W.A.
        • et al.
        What we have learned about the role of 17-alpha-hydroxyprogesterone caproate in the prevention of preterm birth.
        Semin Perinatol. 2016; 40: 273-280
        • Cicinelli E.
        • de Ziegler D.
        • Bulletti C.
        • et al.
        Direct transport of progesterone from vagina to uterus.
        Obstet Gynecol. 2000; 95 (Available at:) (Accessed October 3, 2017): 403-406
        • Boelig R.C.
        • Zuppa A.F.
        • Kraft W.K.
        • et al.
        Pharmacokinetics of Vaginal Progesterone in Pregnancy.
        Am J Obstet Gynecol. 2019; 221
        • O’Brien J.M.
        • Lewis D.F.
        Prevention of preterm birth with vaginal progesterone or 17-alpha-hydroxyprogesterone caproate: A critical examination of efficacy and safety.
        Am J Obstet Gynecol. 2016; 214: 45-56
        • Stewart L.A.
        • Simmonds M.
        • Duley L.
        • et al.
        Evaluating Progestogens for Preventing Preterm birth International Collaborative (EPPPIC): meta-analysis of individual participant data from randomised controlled trials.
        Lancet. 2021; 397: 1183-1194
        • Blake E.J.
        • Norris P.M.
        • Dorfman S.F.
        • et al.
        Single and multidose pharmacokinetic study of a vaginal micronized progesterone insert (Endometrin) compared with vaginal gel in healthy reproductive-aged female subjects.
        Fertil Steril. 2010; 94: 1296-1301
        • Boelig R.C.
        • Della Corte L.
        • Ashoush S.
        • et al.
        Oral progesterone for the prevention of recurrent preterm birth: systematic review and metaanalysis.
        Am J Obstet Gynecol MFM. 2019; 1: 50-62
        • Nold C.
        • Maubert M.
        • Anton L.
        • et al.
        Prevention of preterm birth by progestational agents: what are the molecular mechanisms?.
        Am J Obstet Gynecol. 2013; 208: 223.e1-223.e7
        • Nold C.
        • Jensen T.
        • O’Hara K.
        • et al.
        Replens prevents preterm birth by decreasing type I interferon strengthening the cervical epithelial barrier.
        Am J Reprod Immunol. 2020; 83
        • Kumar D.
        • Springel E.
        • Moore R.M.
        • et al.
        Progesterone inhibits in vitro fetal membrane weakening.
        Am J Obstet Gynecol. 2015; 213 (Mosby Inc): 520.e1-520.e9
        • Furcron A.
        • Romero R.
        • Plazyo O.
        • et al.
        Vaginal progesterone, but not 17-ahydroxyprogesterone caproate, has antiinflammatory effects at the murine maternal-fetal interface.
        Am J Obstet Gynecol. 2015; 213 (Vaginal): e1-e35
        • Coomarasamy A.
        • Williams H.
        • Truchanowicz E.
        • et al.
        PROMISE: First-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages – A randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation.
        Health Technol Assess (Rockv). 2016; 20: 7-91
        • Coomarasamy A.
        • Harb H.M.
        • Devall A.J.
        • et al.
        Progesterone to prevent miscarriage in women with early pregnancy bleeding: The PRISM RCT.
        Health Technol Assess (Rockv). 2020; 24: 1-70
        • Devall A.J.
        • Papadopoulou A.
        • Podesek M.
        • et al.
        Progestogens for preventing miscarriage: a network meta-analysis.
        Cochrane Database Syst Rev. 2021; 2021
        • Coomarasamy A.
        • Devall A.J.
        • Brosens J.J.
        • et al.
        Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.
        Am J Obstet Gynecol. 2020; 223: 167-176
        • Jarde A.
        • Lutsiv O.
        • Beyene J.
        • et al.
        Vaginal progesterone, oral progesterone, 17-OHPC, cerclage, and pessary for preventing preterm birth in at-risk singleton pregnancies: an updated systematic review and network meta-analysis.
        BJOG An Int J Obstet Gynaecol. 2019; 126: 556-567
        • Boelig R.C.
        • Locci M.
        • Saccone G.
        • et al.
        Vaginal progesterone compared with intramuscular 17-alpha-hydroxyprogesterone caproate for prevention of recurrent preterm birth in singleton gestations: a systematic review and meta-analysis.
        Am J Obstet Gynecol MFM. 2022; 4
        • ACOG
        Prediction and Prevention of Spontaneous Preterm Birth: ACOG Practice Bulletin, Number 234.
        Obstet Gynecol. 2021; 138: e65-e90
        • Meis P.J.
        • Klebanoff M.
        • Thom E.
        • et al.
        Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate.
        N Engl J Med. 2003; 348: 2379-2385
        • Blackwell S.C.
        • Gyamfi-Bannerman C.
        • Biggio J.R.
        • et al.
        17-OHPC to Prevent Recurrent Preterm Birth in Singleton Gestations (PROLONG Study): A Multicenter, International, Randomized Double-Blind Trial.
        Am J Perinatol. 2019; 1
        • Society of Maternal Fetal Medicine
        SMFM Statement: Use of 17-Alpha Hydroxyprogesterone Caproate for Prevention of Recurrent Preterm Birth.
        (Accessed November 15, 2022)
        • Boelig R.C.
        • Schoen C.N.
        • Frey H.A.
        • et al.
        Vaginal versus Intramuscular Progesterone for Prevention of Recurrent Preterm Birth (VIP): a randomized controlled trial.
        Am J Obstet Gynecol. 2022; 226: S26
        • Romero R.
        • Conde-Agudelo A.
        • Da Fonseca E.
        • et al.
        Vaginal Progesterone for Preventing Preterm Birth and Adverse Perinatal Outcomes in Singleton Gestations with a Short Cervix: A Meta-Analysis of Individual Patient Data.
        Am J Obstet Gynecol. 2018; 218: 161-180
        • Romero R.
        • Conde-Agudelo A.
        • Rehal A.
        • et al.
        Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis.
        Ultrasound Obstet Gynecol. 2022; 59: 263-266
        • Ward A.
        • Greenberg V.
        • Valcarcel B.
        • et al.
        Intramuscular progesterone in women with twins and a prior singleton spontaneous preterm birth.
        Am J Obstet Gynecol MFM. 2020; 2 (Elsevier Inc)
        • Su L.-L.
        • Samuel M.
        • Chong Y.-S.
        Progestational agents for treating threatened or established preterm labour.
        Cochrane Database Syst Rev. 2014;
        • Guyatt G.H.
        • Oxman A.D.
        • Akl E.A.
        • et al.
        GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables..
        J Clin Epidemiol. 2011; 64: 383-394